Pharmaceutical Standards in Israel and EU Equivalents
Recommendation
10/11 February 2026
Risk analysis, preventive measures and incident management
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The European Parliament accepted the so called ACAA agreement between the European Union and Israel on October 23, 2012. This agreement which had been prepared some time ago has been now finalized.
Acccording to a press release: "The ACAA agreement (Agreements on Conformity Assessment and Acceptance of industrial products) with Israel is a framework agreement that recognizes Israel industrial standards as equivalents to European standards. An appendix regarding pharmaceutical products was added to the vote. The meaning of this is that the European Union will recognize the Israeli pharmaceutical standard, and Israeli pharmaceutical products can now be marketed without delay or further inspection (in parallel to similar marketing of European drugs in Israel). Additional appendixes covering other industrial spheres will be added to the framework agreement in the near future."
Source: Press Release EurActiv
Related GMP News
04.02.2026When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
27.01.2026New Ph. Eur. Publication Schedule
21.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?